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Abstract
 .To compensate for the hypoprotein and hypoalbuminemia of familial amyloidotic polyneuropathy FAP patients, 800 ml
 .  .of fresh frozen plasma FFP was intravenously administered and change in total and variant transthyretin TTR levels were
measured in the plasma. After injection of FFP, total plasma TTR levels were elevated and variant TTR levels decreased
from 24 to 48 h, accompanied by an elevation of plasma total protein, albumin levels and TTR levels. To elucidate the
mechanism of this phenomenon, a large amount of purified normal TTR from normal human plasma was intravenously
injected in mice and FAP patients. By intravenous injection of 3 mg of the purified TTR to C57Black6, the expression of
TTR mRNA decreased from 6 to 24 h post injection, and gradually increased up to 48 h post injection. After injecting
400 mg of normal TTR in each of 3 FAP patients, total plasma TTR levels were elevated and variant TTR levels decreased
significantly from 24 to 48 h. These results suggested that down regulation of the harmful protein by replacement of its
normal form of the protein occurred by this method. This phenomenon should be applied as the basis for one of the useful
methods for decreasing the harmful proteins in the circulation. q 1997 Elsevier Science B.V.
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1. Introduction
Recent studies have revealed that the major com-
ponent of deposited amyloid fibrils in familial amy-
Abbreviations: FAP: Familial amyloidotic polyneuropathy;
TTR: Transthyretin; FFP: Fresh frozen plasma; Trp: Tryptophan.
) Corresponding author. Tel.: q46 785 00 00; fax: q46 90 14
39 86.
 .  .loidotic polyneuropathy FAP Type I Met30 and II
 .  . w xSer84 is a variant transthyretin TTR 1–3 . Many
therapeutic trials have been performed to reduce this
w xharmful protein 4,5 : Plasmapheresis has been ap-
 .plied to FAP patients Met30 to replace the variant
protein with normal TTR, however, this procedure is
an expensive therapy with unexpected risk of bacte-
rial and viral infection as well as abnormal bleeding.
Moreover, because of the rapid plasma half life of
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w xTTR 6 , decreases in plasma variant TTR are tran-
sient, and 2-3 days after the plasmapheresis, rebound
overproduction of the variant protein was observed
w x7 . Immunosorbent absorption using a monoclonal
antibody against the variant TTR has also been at-
w xtempted with the same results 5 .
Since both normal and variant TTR are predomi-
w xnantly synthesized by the liver 8,9 , liver transplanta-
tion for FAP patients is now considered as a promis-
w xing therapy 10–12 . In fact, after liver transplanta-
tion, variant TTR levels in plasma decreased to below
w x1% of those before liver transplantation 9 . Clinical
studies have indicated that autonomic function was
either improved or did not deteriorated after trans-
w xplantation 10–12 . However, transplantation therapy
is limited to early stage FAP patients because the
impairment of peripheral nerves is basically irre-
versible. Liver transplantation in advanced FAP pa-
tients did not provide favorable results during the
clinical course because of cardiac and renal dysfunc-
tions induced by amyloid deposition in the tissues
w x13 . Moreover, liver transplantation is costly and the
history of this therapy is not sufficient to evaluate the
value of this treatment. Until the end of 1995, more
than 140 FAP patients have undergone this surgery
w xand 20-30% of the cases died 14 . In addition, a
shortage of the donor organs has also been a problem.
Patients who undergo the operation must take to
immunosuppressants and may develop acute and
chronic rejection of the transplanted organ or viral or
w xbacterial infections 15 . Thus, an effective non-inva-
sive therapy to prevent amyloid deposition in FAP
 .should be developed in FAP. Another method s
which decrease the plasma level of variant TTR
should be considered effective in slowing the progress
of FAP.
 .It is well documented that FAP Type I Met30
patients show systemic autonomic dysfunctions, such
as orthostatic hypotension, diarrhea, disorders of the
pupils, bladder or rectal disturbances, and abnormal
pattern of sweating and sensory dominant polyneu-
w xropathy 1,16,17 . As the disease progresses, FAP
patients become emaciated and hypoprotein and hy-
w xpoalbuminemia are often observed 1,16–18 . To
compensate for the hypoprotein and hypoalbumine-
 .mia in these FAP patients, fresh frozen plasma FFP
often used to be intravenously injected. It has been
surprising that the variant TTR levels decreased while
levels of total TTR, total protein, and albumin in the
plasma increased. It is possible that some genetic
reaction occurs in response to the transfusion.
This report describes the changes in variant and
normal TTR levels after injecting a large amount of
purified plasma and normal TTR in humans. A mouse
model was also studied, in which changes in both
TTR and mRNA levels after the injection of TTR
were also measured.
2. Patients and methods
2.1. Materials
Normal human plasma was supplied from the
 .Green Cross Corporation Osaka, Japan . Chemicals
used in this study were of analytical grade.
2.2. Animals
Twenty-five grams of male C57Black6 mice were
used.
2.3. Normal TTR injection in mice
Three mg in 100 ml of normal TTR purified from
human plasma was injected into the tail vein of
 .C57Black6 mice ns3 to measure the change in
both plasma TTR and TTR mRNA levels in the liver.
Mice were exsanguinated by bleeding to collect the
plasma and liver samples at 6, 24 and 48 h after the
TTR injection. Control mice did not receive any
injection.
2.4. Patients and the procedure of purified plasma
and normal TTR injection
We examined changes in the plasma normal and
variant TTR levels in the plasma of 2 FAP patients
 .32-year-old and 37-year-old males presenting hy-
poprotein and hypoalbuminemia, after intravenously
injecting 800 ml of normal human FFP. In another
study, 3 FAP patients 32-year-old and a 37-year-old
.males, and a 48-year-old female were investigated
for the change in the plasma normal and variant
TTRs after intravenous injection of 400 mg of puri-
fied normal human TTR. Approval for the human
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studies was obtained from the ethical committee of
Kumamoto University School of Medicine. The na-
ture and aims of the study were explained to all the
subjects who gave their informed consent. All the
patients received the examinations after informed
consent.
2.5. Measurement of plasma total and ˝ariant TTR
le˝els
The total TTR concentration in each plasma sam-
ple was determined by a single radial immunodiffu-
 . w xsion method Behringwerke, Marburg, FRG 19 . To
determine the variant TTR levels, 5ml of the plasma
sample was treated with cyanogen bromide, and then
incubated in 0.1 M Tris–HCl for 12 h. Samples were
then digested with trypsin and assays carried out
 .according to the radioimmunoassay RIA procedure
w xdescribed by Nakazato et al. 20 .
2.6. Measurement of the le˝els of TTR gene
expression in mice
The levels of TTR mRNA expression in the liver
of experimental mice injected TTR were compared
with these injected with saline only. The RNase
protection assay method was used for TTR mRNA
expression determination. To avoid differences due to
the quantity of extracted mRNA in each liver sam-
ples, mouse b-actin gene expression was used as an
internal control.
Total RNA from liver was purified by the guani-
dinium thiocyanate-phenol-chloroform method as de-
w xscribed by Chomczynski et al. 21 . We examined the
levels of both the mouse TTR and b-actin gene
expression in the removed liver using the RNase
protection assay. The RNase protection assay was
performed with an RPA II Ribonuclease Protection
 .Assay Kit Ambion, Austin, TX . An anti-sense cRNA
probe for mouse TTR was prepared from the 397-bp
fragment encompassing nucleotides 61-457 in the
w xmouse TTR sequence of Wakasugi et al. 22 , which
was subcloned into pCR II vector Invitrogen, CA,
.USA . Anti-sense cRNA probe for mouse b-actin
was obtained from the 0.2 kb Xba I-Hinc II fragment
w xof mouse b-actin cDNA 23 , which was subcloned
 .  .into pBluscript II SK q Strategene, CA, USA .
All probes were labeled with alpha-32P-CTP. The
probes were hybridized at 458C for 16 h with 2.5 mg
of total RNA derived from the livers. The assay was
performed as described by the manufacturer. Pro-
tected cRNA fragments were electrophoresed through
6% polyacrylamide gels. The radioactivities of the
bands corresponding to protected cRNA fragments of
the mouse TTR and b-actin genes were counted
using a BAS 2000 Image Analyzer Fuji Film, Tokyo,
.Japan and the ratios of the mouse TTR mRNA to
b-actin mRNA were analyzed.
2.7. Purification of normal TTR from the plasma
 .Fraction IV Fr. IV was purified from 200 l of
normal human plasma by Cohn’s ethanol fraction
w xmethod 24 . The source plasma met the standards
then in effect for source plasma negative for hepati-
tis B surface antigen, anti-hepatitis C antibody, and
anti-HIV-I-antibody, and alanine aminotransferase
.level less than twice of the upper limit of normal .
Ten kg of Fr. IV was suspended in 30 l of 0.15 M
NaCl, 0.02 M Tris–HCl buffer, pH 7.6 and the mix-
ture was stirred for 1 h at 48C. After filtration using a
 .filter TOYO-roshi No.2, Japan with celite, the PH
of the collected filtrate was adjusted again to pH 7.6,
at 48C, and the solution was kept at 608C for 10 h to
inactivate viruses. After the incubation, the pH of the
solution was readjusted to pH 7.6, 150 grl of
 .polyethyleneglycol PEG 4000 was added and stirred
for 1 h at 48C. Then, the mixture was centrifuged at
4000 rpm for 30 min to separate the precipitate. The
pH of the supernatant was adjusted to 7.6. One kg of
 .DEAE-Sepharose fast flow Pharmacia was added to
this solution and mixed. The resin was then washed
with 3 resin volumes of 0.02 M Tris, 0.1 M NaCl, pH
7.6 on a glass filter. After washing, 1 l of 0.02 M
Tris, 0.5 M NaCl, Tris–HCl buffer, pH 7.6, was used
to elute the TTR. After the procedure, 175 grl of
NaCl was added to the TTR elution and the pH was
readjusted to 7.6. 1.5 kg of Phenyl-Sepharose High
 .Performance Pharmacia was added to the TTR con-
taining mixture. The resin was washed with three
resin volumes of 0.02 M Trs, 3 M NaCl, pH 7.6 on a
glass filter. The TTR containing fractions were col-
lected as the pass-through and the resoluting solution
was concentrated and dialyzed by ultrafiltration
 .Model Minisette, 10 kD-OMEGA, Filtron, USA .
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2.8. Electrophoresis on cellulose acetate membrane
 .A Sepratek chamber Gelman, FRG , Microzone
Plus cellulose membrane Beckman Instruments In-
. ternational SA, Switzerland , Veronal buffer pH 8.6,
. T s0.09 and Ponceau 3R Beckman Instruments1r2
. w xInternational SA, Switzerland were used 25 .
2.9. Statistical analysis
Statistical evaluation was performed by the paired
t-test. A p value -0.05 was taken to be statistically
significant.
3. Results
3.1. Change in plasma normal and ˝ariant TTR
le˝els after drip infusion of purified plasma
To compensate for hypoprotein and hypoalbumine-
mia in the 2 FAP patients described previously,
800 ml of human FFP was intravenously injected
during 3 h. Fig. 1 represents the change in both total
and variant TTR levels in the 37-year-old male FAP
 .patient: Total TTR levels normal plus variant TTR
 .were elevated 118% increase while the variant form
 .of TTR was reduced 39% decrease until 24 h after
 .infusion Fig. 1 . Increase in total TTR and decrease
in variant TTR showed mirror image. Plasma total
Fig. 1. Change in plasma total and variant TTR after a large
amount of plasma infusion. Eight hundred ml of plasma was drip
infused intravenously into a 37-year-old male FAP patient in 3 h.
Open circles: plasma total TTR, and closed circles: variant TTR.
Fig. 2. Electrophoresis of the purified TTR. Electrophoresis was
 .  .performed as described in the text. 1 standard serum, 2
 .purified TTR, and 3 TTR purchased from Sigma. The arrow
and the triangle indicate TTR and albumin, respectively. ) P -
0.05.
protein and albumin levels increased from 4.8 to
5.8 grdl and from 2.4 to 3.3 grdl, respectively just
after the purified plasma infusion.
3.2. Preparation of purified normal TTR
As described previously, purified normal TTR was
prepared from 400 l of bacterial- and viral- free nor-
mal plasma. Electrophoresis revealed that most of the
purified protein was TTR. A small amount of celro-
 .plasmin was present in the extracted sample Fig. 2 .
No other special proteins were contaminated. The
purity of TTR extracted from plasma was calculated
to be 90% by high performance liquid chromatogra-
 .phy HPLC analysis. HPLC analysis also revealed
no quantitative difference in the TTR itself before or
after incubation of the TTR containing samples at
 .608C for 1 h data not shown .
3.3. Change in plasma TTR and TTR mRNA le˝els in
mice after administration of a large amount of TTR
3 mg of purified human TTR were administered to
C57Black6 mice as previously described. The plasma
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level of human TTR increased to 233.6"8.9 mgrdl
just after TTR injection and decreased to 59.7"
1.2 mgrdl 24 h after the injection. This continued
Fig. 3. Change in plasma TTR and the liver mRNA levels after a
large amount of TTR injection in mice. After injecting 3 mg of
normal TTR purified from human plasma into C57Black6 mice,
changes in the liver TTR mRNA were measured as described in
the text. Each of these mice was exsanguinated by bleeding to
collect the liver samples at 0, 6, 24 and 48 h after the TTR
 .injection. A Protection cRNA fragments from TTR and -actin
mRNA were electrophoresed through a 6% polyacrylamide gel.
Lanes represent 1–3, time 0; 4–6, 6 h; 7–9, 24h; 10–12, 48 h
after the injection, 13, digested probe; 14, undigested probe
aliquot of the hybridization solution containing the cRNA probe
for b-actin; and 15, undigested probe aliquot of the hybridization
solution containing the cRNA probe for TTR. “T: TTR, and
 .“A: b-actin. B The radioactivities of the bands corresponding
to the protected cRNA fragments of b-actin and TTR as counted
 .using a BAS 2000 Image Analyzer Fuji Film, Tokyo, Japan .
The values were expressed as the ratio of the radioactivities of
TTR to b-actin. )P-0.05, ))P-0.01.
Fig. 4. Change in both total and variant TTR levels after a large
amount of TTR injection in FAP patients. Four hundred mg of
normal TTR was injected to a 47-year-old female FAP patient.
Open circles: total TTR, and closed circles: the variant TTR.
Time 0 indicates the point of injection.
 .until the level was below 4 mgrdl at 48 h. Fig. 3 A
shows electrophoresis of TTR and b-actin mRNA
through a 6% polyacrylamide gel fragments. mRNA
decreased from 6 h after the administration of TTR
and continued for 24 h. However, after 48 h, slight
overexpression of the TTR gene was observed Fig.
 ..3 B .
3.4. Change in plasma normal and ˝ariant TTR
le˝els in FAP patients after administration of a large
amount of TTR
After infusing 400 mg of normal human TTR in
each of 3 FAP patients as previously described,
plasma variant TTR levels transiently decreased in all
patients average: 20.3"4.9% decrease in variant
.TTR . Fig. 4 represents the changes of total and
variant TTR of a 47-year-old female FAP patient
after the injection. Plasma total TTR levels increased
 .from 22.5 to 57.5 mgrdl 256% increase and the
variant TTR levels decreased from 8.4 to 6.2 mgrdl
 .26.2% decrease 24 h after the injection. This de-
crease continued at least until day 7 after the injec-
 .tion Fig. 4 . In a 32-year-old male FAP patient,
plasma total TTR increased from 29.5 to 55.6 mgrdl
 .189% increase and the variant levels decreased
from 9.7 to 8.0 mgrdl 42 h after the injection 21.3%
.decrease . In a 37-year-old male FAP patient, the
plasma total TTR increased from 30.5 to 57.2 mgrdl
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 .155% increase , while variant TTR levels decreased
 .from 8.7 to 7.1 mgrdl 19.5% decrease 24 h after the
injection. Variant TTR levels at day 1, 3, 5 and 7
showed comparably lower levels than before and just
after the TTR injection. Total plasma TTR levels of 3
patients were elevated from 27.5"4.4 to 56.8"
 .1.0 mgrdl p-0.01 and variant TTR levels de-
 .creased from 8.9"0.7 to 7.1"0.9 mgrdl P-0.05
from 24 to 48 h after the injection.
4. Discussion
We presented data in this report that the variant
TTR production is suppressed by intravenous admin-
istration of a large amount of normal TTR. This
regulation system of the normal TTR gene was also
observed in mice. Since mice TTR has about 70%
homology in their amino acid sequence with that of
w xhuman TTR 22 , it is also natural to observe the
down regulation in mice by the replacement of hu-
man normal protein. From these data, we demon-
strated that artificial modulation of TTR protein syn-
thesis may be possible by administrating a large
amount of normal protein intravenously.
Since both normal and variant TTR are predomi-
w xnantly synthesized by the liver 8,26 , liver transplan-
tation of FAP patients is now considered as a promis-
w xing therapy 10–12 . After liver transplantation, vari-
ant TTR levels in the plasma decreased to below 1%
of those before liver transplantation and clinical find-
ings were improved or not worse after liver transplan-
w xtation 9 . Thus, the reduction of plasma variant TTR
levels may be one way to slow down the progression
of FAP.
Injection of 400 mg of the purified TTR protein
injection in each of 3 FAP patients increased plasma
total TTR levels by 200"32.9%, however, the vari-
ant TTR was decreased by 20.7"4.8% from the
initial levels. Although the presented decrease ratio in
variant TTR was rather small, a significant down
regulation of TTR gene was observed through the
change in variant TTR. We also assayed IL-1, IL-6
and IL-8 during the trial, but found no correlation
with the change in normal and variant TTR levels.
Moreover, during the study, neither C-reactive pro-
 .tein CRP nor ESR elevation was seen in the pa-
tients. Elevation of fever or change in apetite were
not observed during this study. In the mice injected
normal human TTR, neither CRP nor ESR were
observed. These results suggest that the reduction of
variant TTR in the circulation did not result from
some inflammatory responses due to the injection
procedure or injected protein. These patients were
heterozygotes, thus half of the TTR gene is a variant
w xform 27 . Therefore, we calculate that 40% of the
initial gene expression of TTR including normal and
variant forms may be decreased by the single injec-
tion of a large amount of normal TTR. Thus, a much
more larger decrease in variant TTR may be expected
w xin homozygote FAP patients 28 . Since the increase
in total TTR levels elevated by the injection did not
w xlast more than 2 days due to its rapid turn over 6,9 ,
variant TTR levels were not suppressed for long
duration. Although we did not administer repeated
injections of TTR to avoid immuno-allergic re-
sponses, repeated administration of TTR would be
needed to regulate the TTR gene.
Connors et al. reported that depressed plasma TTR
concentrations in FAP patients did not correspond to
the elevations in acute phase proteins, such as C-reac-
w xtive protein and serum amyloid P component 29 . In
fact, the 3 FAP patients examined in our study showed
low levels of plasma TTR like other advanced FAP
patients, so when we administer a large amount of
TTR to FAP patients in the early stages, we expect a
larger decrease in the variant TTR levels in the
plasma.
TTR has been used as an index of protein and
w xenergy malnutrition 30 . Its use as a nutritional index
was based on the observation that a decrease in TTR
was comparably restored during dietary protein re-
plenishment. Compared with other plasma proteins,
such as albumin and transferrin, the TTR response to
w xdietary protein replenishment was faster 29,30 . In
fact, mRNA levels of plasma proteins in rat liver
change rapidly during protein depletion and refeeding
w x31,32 .
The amino acid sequences of both TTR and retinol
binding protein are characterized by an unusually
 . w xhigh tryptophan Trp content 33,34 : Compared with
other plasma proteins, such as albumin, TTR is a Trp
rich molecule and is highly correlated with the nutri-
tional levels. When emaciation progressed, the plasma
level of TTR significantly decreases. Trp accounts for
the lowest concentration of all amino acids in the
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w xusual foodstuffs and in mammalian tissues 35 .
Hence, it is tempting to speculate that the production
of TTR is particularly sensitive to food protein re-
striction. In fact, most FAP patients become emaci-
ated as the disease progresses because of malabsorp-
tion in the intestine and severe diarrhea due to amy-
loid deposition. We examined the plasma levels of
amino acids, resulting in the specific decrease in Trp
 .in FAP patients data not shown . Trp is one of
indispensable amino acids in mammalian body. Rask
et al. and Osborne et al. reported that a Trp deficient
diet induced body weight reduction, which implies
 .substantial tissue mainly muscle mass depletion
w x36,37 . These results suggest that administration of
the benign TTR also showed a beneficial effect on
preventing the emaciation found in FAP.
It is well known that normal TTR behaves as a
tetrameter in the circulation. Perturbation of this te-
trameric protein may lead to amyloid fibril formation
w x38 . During and after the administration, no obvious
clinical or physiological changes were observed in
the patients examined.
Recently, a large amount of intravenous immuno-
globulin therapy has been performed in various dis-
eases. In this therapy, it is well known that the
harmful antibodies can be suppressed by intravenous
administration of immunoglobulin, but the precise
mechanism for the effect has been unclear. Saleh et
al. reported that administered immunoglobulin makes
aggregates on the monocyte surface, which sup-
w xpresses further antibody generation 39 . Although the
mechanism of a large amount of immunoglobulin
administration therapy may be different from our
trial, such supplementary therapies should be further
studied.
It should be noted that, when we administer FFP
or purified albumin to patients with hypoprotein and
hypoalbuminemia, such down regulation of albumin
gene may occur during the administration.
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